1 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Ore Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis ORE1001, Placebo - Mild to Moderate Ulcerative Colitis | Phase 1 / Phase 2 | Unknown | Ore Pharmaceuticals, Inc. | 50 | 2009-12-01 | 2011-06-08 |
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid (1)
Canada (1) · India (1)